



**Ref. No.: EIKO/BSE/2023-24/55**

**Date: 08<sup>th</sup> February 2024**

To,  
Corporate Services Department,  
**BSE Limited**,  
P J Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

Scrip Code: 540204

**Sub: Outcome of the Board Meeting**

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Thursday, 08th February, 2024, Board, inter-alia, considered and approved the Unaudited Financial Results for the Quarter and nine months ended 31<sup>st</sup> December, 2023.

The Statutory Auditors have carried out a “Limited Review” of the Unaudited Financial Results for the Quarter and nine months ended 31<sup>st</sup> December 2023. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company

The said results shall be published in one English and one vernacular newspaper as required. This intimation is also available on the Company’s website at [www.eikolifesciences.com](http://www.eikolifesciences.com)

The Meeting was commenced at 5.15 PM and concluded at 5.45 PM.

**For Eiko Lifesciences Limited**

**Jaid Kojar**  
**Chief Financial Officer**

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER 2023**

(₹ in Lakhs, except per share data)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31-03-2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
<b>1</b>	Revenue from operations	661.09	641.27	437.58	1,953.14	1,172.69	1,832.14
	Other income	1.44	2.81	18.61	6.98	64.68	85.48
	<b>Total revenue</b>	<b>662.53</b>	<b>644.09</b>	<b>456.18</b>	<b>1,960.11</b>	<b>1,237.37</b>	<b>1,917.62</b>
<b>2</b>	<b>Expenses</b>						
	Cost of Material consumed	618.43	660.21	233.15	1,880.20	773.18	1,366.49
	Changes in inventories of finished stock and work-in-progress	(24.08)	(89.26)	150.22	(113.79)	242.20	242.85
	Employee benefits expense	6.49	4.95	7.85	16.78	22.37	28.71
	Depreciation and amortization expense	16.09	16.06	15.83	48.20	47.34	63.28
	Finance Cost	2.50	6.10	1.31	11.97	11.57	15.03
	Other expenses	13.99	29.86	13.90	60.63	75.89	98.64
	<b>Total expenses</b>	<b>633.42</b>	<b>627.93</b>	<b>422.25</b>	<b>1,903.98</b>	<b>1,172.54</b>	<b>1,815.00</b>
<b>3</b>	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>29.10</b>	<b>16.16</b>	<b>33.93</b>	<b>56.13</b>	<b>64.83</b>	<b>102.62</b>
<b>4</b>	<b>Tax expense:</b>						
	a. Current tax	-	-	-	-	0.01	4.84
	b. Deferred tax	5.35	4.07	8.53	12.28	16.24	20.91
<b>5</b>	<b>Profit/(Loss) from ordinary activities after tax</b>	<b>23.76</b>	<b>12.09</b>	<b>25.40</b>	<b>43.85</b>	<b>48.59</b>	<b>76.88</b>
<b>6</b>	<b>Other Comprehensive Income (OCI)</b>						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	-	-	3.21	3.21
	Income tax relating to these items	-	-	-	-	(0.81)	(0.81)
	<b>Total Other Comprehensive Income (OCI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2.40</b>	<b>2.40</b>
	<b>Profit/(Loss) for the Period</b>	<b>23.76</b>	<b>12.09</b>	<b>25.40</b>	<b>43.85</b>	<b>50.99</b>	<b>79.28</b>
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	997.95	997.95	831.63	997.95	831.63	831.63
<b>7</b>	<b>Earnings Per Share (EPS) (Not annualised)</b>						
	(1) Basic	0.24	0.12	0.26	0.45	0.50	0.79
	(2) Diluted	0.24	0.12	0.26	0.45	0.50	0.79



**Notes:**

1. The above Financial Results for the Quarter and Nine Months ended 31<sup>st</sup> December 2023 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Thursday, 8<sup>th</sup> February 2024. The Statutory Auditors have carried out Limited Review of above results and expressed an unmodified opinion on these financial results.
2. The Company has a single business segment, namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
3. The Company issued 55,44,178 equity shares of face value of ₹ 10/- each ('Rights Equity Shares') to the Eligible Equity Shareholders at an issue price of ₹45 per Rights Equity Share (including premium of ₹ 35 per Rights Equity Share). The Rights Equity Shares were issued as partly paid-up and an amount of ₹13.50 per Rights Equity Share was payable on application (of which ₹ 3 towards face value of Rights Equity Share and ₹ 10.5 towards premium amount of Rights Equity Share).
4. The Right Issue Committee of the Board of Directors of the Company at its meeting held on Thursday, 14<sup>th</sup> December 2023 approved the making of First and Final Call of Rs. 31.50/- (Rupees Thirty-One and Fifty Paise Only) on 55,44,178 Partly Paid-up Equity Shares. The Company fixed Friday, 22<sup>nd</sup> December 2023 as the Record Date for the purpose of determining the holders of Partly Paid-up Equity Shares to whom the call notice with the dispatched for payment of the call. Pursuant to IND AS 33, basic and diluted earnings per share for the previous periods have been restated for the bonus element in respect of right issue made during the quarter and Nine Months ended 31<sup>st</sup> December 2023.
5. Other Expenses of Quarter and Nine Months year ended 31.12.2023 includes expenses incurred on account of issue of Equity Shares on rights basis amounting to ₹6.37 Lakhs and ₹26.06.
6. Previous quarter figures have been regrouped reclassified wherever necessary, to make them comparable.

**For Eiko LifeSciences Limited**

*L.K. Kabra*

**Laxmikant Kabra**  
Chairman  
**Din: 00061346**



**Date: 8<sup>th</sup> February 2024**  
**Place: Thane**

**Independent Auditor's Review Report on the Quarterly and Nine Months Ended Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To the Board of Directors  
Eiko Lifesciences Limited  
(Formerly known as Narendra Investments (Delhi) Limited)**

1. We have reviewed the accompanying statement of Unaudited Financial Results of **Eiko Lifesciences Limited** (the "Company") for the quarter and Nine Months ended December 31, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

**For Thanawala & Company**  
Chartered Accountants  
**Firm Reg. No.: 110948W**



**CA Vijay Thanawala**  
Proprietor  
**Membership No.: 015632**



**Place: Mumbai**  
**Date: 8<sup>th</sup> February 2024**

**UDIN: 24015632BKGWVM8484**